CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel
The FDA is slated to decide on approving Capricor’s drug for the treatment of Duchenne muscular dystrophy by November 22. Craig M. McDonald, a lead investigator for Capricor’s trial, shared on LinkedIn that 28 physician-scientists who participated in Capricor’s late-stage HOPE-3 trial had written to FDA leadership, urging the agency to approve the drug. The … Read more